Literature DB >> 20962589

p53-dependent repression of polo-like kinase-1 (PLK1).

Lynsey McKenzie1, Sharon King, Lynnette Marcar, Sam Nicol, Sylvia S Dias, Katie Schumm, Pamela Robertson, Jean-Christophe Bourdon, Neil Perkins, Frances Fuller-Pace, David W Meek.   

Abstract

PLK1 is a critical mediator of G₂/M cell cycle transition that is inactivated and depleted as part of the DNA damage-induced G₂/M checkpoint. Here we show that downregulation of PLK1 expression occurs through a transcriptional repression mechanism and that p53 is both necessary and sufficient to mediate this effect. Repression of PLK1 by p53 occurs independently of p21 and of arrest at G₁/S where PLK1 levels are normally repressed in a cell cycle-dependent manner through a CDE/CHR element. Chromatin immunoprecipitation analysis indicates that p53 is present on the PLK1 promoter at two distinct sites termed p53RE1 and p53RE2. Recruitment of p53 to p53RE2, but not to p53RE1, is stimulated in response to DNA damage and/or p53 activation and is coincident with repression-associated changes in the chromatin. Downregulation of PLK1 expression by p53 is relieved by the histone deacetylase inhibitor, trichostatin A, and involves recruitment of histone deacetylase to the vicinity of p53RE2, further supporting a transcriptional repression mechanism. Additionally, wild type, but not mutant, p53 represses expression of the PLK1 promoter when fused upstream of a reporter gene. Silencing of PLK1 expression by RNAi interferes with cell cycle progression consistent with a role in the p53-mediated checkpoint. These data establish PLK1 as a direct transcriptional target of p53, independently of p21, that is required for efficient G₂/M arrest.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962589      PMCID: PMC3055203          DOI: 10.4161/cc.9.20.13532

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  49 in total

1.  Transcriptional repression of the anti-apoptotic survivin gene by wild type p53.

Authors:  William H Hoffman; Siham Biade; Jack T Zilfou; Jiandong Chen; Maureen Murphy
Journal:  J Biol Chem       Date:  2001-11-19       Impact factor: 5.157

Review 2.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

Review 3.  Regulation of the G2/M transition by p53.

Authors:  W R Taylor; G R Stark
Journal:  Oncogene       Date:  2001-04-05       Impact factor: 9.867

4.  Polo-like kinase-1 is a target of the DNA damage checkpoint.

Authors:  V A Smits; R Klompmaker; L Arnaud; G Rijksen; E A Nigg; R H Medema
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

5.  Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion.

Authors:  M A van Vugt; V A Smits; R Klompmaker; R H Medema
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

Review 6.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

7.  Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation.

Authors:  Hyungshin Yim; Raymond L Erikson
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

8.  Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA.

Authors:  Xiaoqi Liu; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

Review 9.  Tumor suppressive functions of p53.

Authors:  Jack T Zilfou; Scott W Lowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11       Impact factor: 10.005

10.  Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.

Authors:  Birgit Spänkuch-Schmitt; Georg Wolf; Christine Solbach; Sibylle Loibl; Rainald Knecht; Manfred Stegmüller; Gunter von Minckwitz; Manfred Kaufmann; Klaus Strebhardt
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

View more
  68 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  The RP-p53-Mdm2 pathway: a new link to genetic integrity?

Authors:  Rebeca A Frum; Yanping Zhang
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

3.  Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Sankaranarayanan Kannan; Marisa J L Aitken; Shelley M Herbrich; Leonard S Golfman; Mandy G Hall; Duncan H Mak; Jared K Burks; Guangchun Song; Marina Konopleva; Charles G Mullighan; Joya Chandra; Patrick A Zweidler-McKay
Journal:  Mol Cancer Ther       Date:  2019-06-21       Impact factor: 6.261

4.  A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Authors:  Weiwei Shan; Patricia Y Akinfenwa; Kari B Savannah; Nonna Kolomeyevskaya; Rudolfo Laucirica; Dafydd G Thomas; Kunle Odunsi; Chad J Creighton; Dina C Lev; Matthew L Anderson
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

5.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

Authors:  Long Chen; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

6.  E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression.

Authors:  Luis A Carvajal; Pierre-Jacques Hamard; Crystal Tonnessen; James J Manfredi
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

Review 7.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

8.  Cyclin B2 and p53 control proper timing of centrosome separation.

Authors:  Hyun-Ja Nam; Jan M van Deursen
Journal:  Nat Cell Biol       Date:  2014-04-28       Impact factor: 28.824

Review 9.  Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis.

Authors:  J Jeffery; D Sinha; S Srihari; M Kalimutho; K K Khanna
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.